ArticleScientific reports2025
Combined experimental and in silico elucidation of KP27 endolysin reveals a phage derived antibacterial with pH and thermal robustness.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage-derived endolysins are potent antibacterial agents capable of lysing multidrug-resistant bacteria by cleaving peptidoglycan bonds. This study characterizes KP27 endolysin, a 131-amino acid enzyme encoded by the Klebsiella phage KP27, which exhibits L-alanyl-D-glutamate endopeptidase activity that is effective against both gram-positive and gram-negative bacteria. Recombinant KP27 was expressed and purified with a molecular weight of approximately 15 kDa. It demonstrated dose-dependent bactericidal activity, reducing Staphylococcus aureus and Escherichia coli viability by up to 80% and 65%, respectively, at 8 µg/mL. Time-kill assays revealed rapid bacterial lysis within 60 min at 2× MIC (16 µg/mL for S. aureus and 32 µg/mL for E. coli with EDTA). Thermal assays indicated substantial stability up to 50 °C. Hemolytic tests revealed minimal cytotoxicity, with less than 5% hemolysis at concentrations as high as 100 µg/mL. AlphaFold2 modeling and molecular docking identified key substrate-binding residues consistent with L-alanyl-D-glutamate cleavage specificity. Circular dichroism spectroscopy revealed a predominantly alpha-helical secondary structure (~ 55%) at pH 8.0, which was correlated with maximal enzymatic activity; this helicity decreased to ~ 44-49% at pH 6.0 and 10.0, which coincided with reduced activity. Intrinsic fluorescence indicated a well-folded tertiary structure under optimal conditions, whereas ANS fluorescence confirmed minimal exposure of hydrophobic residues at pH 8.0. They revealed that KP27 maintains a predominantly alpha-helical secondary structure and a tightly folded tertiary conformation at an optimal pH of 8.0, which is strongly correlated with maximal enzymatic activity. Together, these data highlight KP27 endolysin as a stable, broad-spectrum antimicrobial enzyme with promising therapeutic potential against resistant bacterial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.